Clinical trials: cyclosporine, completed
Acute Myelogenous Leukemia
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total body irradiation, before peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00303667
- Testing
- aldesleukin, natural killer cells, cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myelodysplastic Syndromes
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00008151
- Testing
- cyclosporine, fludarabine phosphate, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Dry Eye Syndromes
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
The purpose of this clinical Study is TJCS Eye Drops 0.05%(Cyclosporine ophthalmic nano-emulsion) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group…
- Trial name
- NCT02461719
- Testing
- CYPORIN N EYE DROPS 0.05%(TJCS eye drop), Restasis
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
This phase II trial studies how well reduced intensity donor peripheral blood stem cell (PBSC) transplant works in treating patients with de novo or secondary acute myeloid leukemia (AML) in remission.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00045435
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, fludarabine phosphate, total-body irradiation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Fred Hutchinson Cancer Center
Dry Eye Disease
Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects with Dry Eye Disease
- Trial name
- NCT03287635
- Testing
- Corticotropin 80Unit/Ml Repository Injection
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Epiphora
Topical Cyclosporine-A for Management of Epiphora
to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis
- Trial name
- CSA-epiphora (NCT04637633)
- Testing
- topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,
- Where
- Kuwait
- Volunteers
- 12 people
- Sponsor
- Farwaniya Hospital
Bronchiolitis Obliterans, Immunosuppression
Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation
The purpose of the study is to compare efficacy and safety of two different immunosuppressive regimens for prevention of bronchiolitis obliterans syndrome (BOS) (chronic lung allograft rejection)after lung transplantation…
- Trial name
- EAILTX (NCT01429844)
- Testing
- Tacrolimus, Cyclosporine
- Where
- 14 sites in Australia, Austria and 4 more
- Volunteers
- 274 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Traumatic Brain Injury
Copenhagen Head Injury Ciclosporin (CHIC) Study
This is an open label study on the pharmacokinetics and safety of ciclosporin in patients with severe traumatic brain injury, who require intensive care unit admission and monitoring of intracranial pressure via a ventricular…
- Trial name
- CHIC (NCT01825044)
- Testing
- NeuroSTAT 5 mg/kg/day, NeuroSTAT 10 mg/kg/day
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- NeuroVive Pharmaceutical AB
Uveitis
Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A
Study efficacy of everolimus on course of uveitis: obtain quiescence of inflammation after start of treatment duration to obtain quiescence of inflammation number of patients with quiescence of inflammation
- Trial name
- NCT00803816
- Testing
- everolimus
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Carsten Heinz
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Renal Transplantation
Interaction Between Rimonabant and Cyclosporine and Tacrolimus
The major cause of premature death in renal transplant recipients is cardio-vascular disease. In addition, obesity is becoming a major problem in this patient population.
- Trial name
- RIMONA-PILOT (NCT00525681)
- Testing
- cyclosporine A, tacrolimus
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- University of Oslo School of Pharmacy
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Fanconi's Anemia
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
OBJECTIVES: I. Determine the probability of engraftment with total body irradiation, cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically identical donor, T-cell depleted hematopoietic cell…
- Trial name
- NCT00005898
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Dry Eye Disease (DED), Asthenopia
Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT
At present, research on cyclosporine mainly focuses on patients with moderate to severe dry eye. Based on the importance of the vicious cycle of inflammation in the pathogenesis of dry eye and the mechanism of cyclosporine…
- Trial name
- NCT06981104
- Testing
- 0.05% cyclosporine eyedrops, 0.1% sodium hyaluronate eye drop
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Juvenile Dermatomyositis
Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
This is a 5-year project, involving 185 partners from 46 countries ((110 in 21 European Union (EU) States and 75 in 25 extra-EU States)), with a randomised clinical trials (RCT) in juvenile dermatomyositis (JDM): 5-year phase III…
- Trial name
- PRINTOJDMTR (NCT00323960)
- Testing
- 3 MPDN pulse + PDN, 3 MPDN pulse + PDN + CSA, 3 MPDN pulse + PDN + MTX
- Where
- Italy
- Volunteers
- 139 people
- Sponsor
- Istituto Giannina Gaslini
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Trial name
- NCT00088543
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 14 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Sever Aplastic Anaemia
A Trial of Hetrombopag in Healthy Subjects
This is a single-center, single-arm, open-label, self-controlled, phase I clinical study. A total of 26 male or female healthy subjects are intended to be enrolled to evaluate the PK drug-drug interaction between ciclosporin and…
- Trial name
- NCT05088174
- Testing
- Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatitis C
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and…
- Trial name
- NCT01038167
- Testing
- telaprevir, cyclosporine, tacrolimus
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Immunosuppression, Renal Failure
Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
This study will examine the renal sparing impact of implementing a strategy of conversion to everolimus from a calcineurin inhibitor based immunosuppressive protocol at 3 months post liver transplant
- Trial name
- NCT01936519
- Testing
- Arm A: Everolimus, Calcineurin Inhibitor
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Milton S. Hershey Medical Center
Severe Atopic Dermatitis
Verification Study of Ciclosporin for Atopic Dermatitis
To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00232076
- Testing
- ciclosporin
- Sponsor
- Novartis Pharmaceuticals